COGNITION THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
COGNITION THERAPEUTICS INC. - More news...
COGNITION THERAPEUTICS INC. - More news...
- Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
- Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
- Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
- Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
- Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
- Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
- Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
- Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
- Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
- Cognition Therapeutics Announces Proposed Public Offering of Common Stock
- Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
- Cognition Therapeutics to Present at the TD Cowen Health Care Conference
- New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
- Cognition Therapeutics CEO Issues Letter to Shareholders
- Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
- Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
- Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
- Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD
- Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD
- Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications
- Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD
- Cognition Therapeutics Announces Participation in Upcoming September Conferences
- Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
- Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023
- Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD
- Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease
- Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
- Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023
- Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches